Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
Abstract Parkinson’s disease (PD) is characterized by motor deficits and a wide variety of non-motor symptoms. The age of onset, rate of disease progression and the precise profile of motor and non-motor symptoms display considerable individual variation. Neuropathologically, the loss of substantia...
Main Authors: | Christian U. von Linstow, Ziv Gan-Or, Patrik Brundin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-10-01
|
Series: | Translational Neurodegeneration |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40035-020-00218-x |
Similar Items
-
Modeling Parkinson’s Disease in Drosophila: What Have We Learned for Dominant Traits?
by: Yulan Xiong, et al.
Published: (2018-04-01) -
GBA-Associated Synucleinopathies: Prime Candidates for Alpha-Synuclein Targeting Compounds
by: Kathrin Brockmann, et al.
Published: (2020-09-01) -
Glucocerebrosidase Mutations and Synucleinopathies. Potential Role of Sterylglucosides and Relevance of Studying Both GBA1 and GBA2 Genes
by: Rafael Franco, et al.
Published: (2018-06-01) -
Analysis of α-synuclein levels related to LRRK2 kinase activity: from substantia nigra to urine of patients with Parkinson’s disease
by: Daleum Nam, et al.
Published: (2021-01-01) -
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease
by: Chen Yao, et al.
Published: (2010-10-01)